{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"5.49","upperLimit":"NA","value":"10.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Hepatocellular Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.01","upperLimit":"12.65","value":"11.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Triple Negative Breast Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"25.03","upperLimit":"NA","value":"30.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Immune Checkpoint-naïve Melanoma"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"4.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Relapsed Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.51","upperLimit":"19.45","value":"14.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"NSCLC Total"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.13","upperLimit":"18.86","value":"13.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Renal Cell Carcinoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.24","upperLimit":"13.34","value":"9.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of the Head and Neck"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.41","upperLimit":"22.74","value":"15.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"Transitional Cell Carcinoma of the GU Tract"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.29","upperLimit":"7.79","value":"5.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"2.56","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Gastric Cancer"},{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"6.11","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"MSI high Colorectal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.01","upperLimit":"10.91","value":"7.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"DLBCL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"191"}],"units":"Participants"}],"description":"The duration of disease control is the time from the treatment start date to the first objective response of PD (by irRECIST v1.1 or Lugano Classification), death, or last tumor assessment date (if PD/death not present), for subjects with best overall response of SD or better.","dispersionType":"90% Confidence Interval","groups":[{"description":"Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.","id":"OG000","title":"Epacadostat 100 mg BID+ Pembrolizumab 200 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"The Efficacy Evaluable Population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab). Number analyzed indicated participants analyzed in the respective tumor type. The median time and the 90% CI were estimated using Kaplan-Meier method.","reportingStatus":"POSTED","timeFrame":"Up to 54 months","title":"Phase 2: Duration of Disease Control","type":"SECONDARY","unitOfMeasure":"Months"}